

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Betz, et al.

Group No.:

Serial No.: Filed Herewith

Examiner:

Filed: 07/07/05

For: Method for Inhibiting the Replication of Herpes Viruses

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed *before* the mailing date of the first Office action on the merits.

FEE PAYMENT


Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No.: 29,862

Telephone: (203) 812-2786

Date: 07/07/05


Barbara A. Shimei
Attorney for Applicant(s)
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516

Form PTO-1449 (Modified)	Department of Commerce Patent and Trademark Office	Serial No. Filed Herewith	Art. Unit	Filing Date 07/07/05	App. No. / Pub. No. 107541886
INFORMATION DISCLOSURE CITATION		Applicant(s) Betz, et al.			

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	U1	20	01	00	07	8	7	7	07/12/01	Burton, et al.	514	414	11/10/99
	U2	6	0	5	4	4	7	2	04/25/00	Armistead, et al	514	374	04/02/97

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F1	0	0	0	9	1	5	8	24/02/00	WO				
	F2	0	3	0	9	7	5	95	27/11/03	WO				
	F3	0	8	6	0	7	0	0	26/08/98	EP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

R1	Sherman, et al., Characterization of Intranuclear Capsids Made by ts Morphogenic Mutants of HSV-1, Virology, <u>163</u> (2): 471-480 (1988).
R2	Weller, et al. Genetic and Phenotypic Characterization of Mutants in Four Essential Genes That Map to the Left Half of HVS-1 U _L DNA, Virology, <u>161</u> (1): 198-210 (1987).
R3	Plotkin, et al., Candidate Cytomegalovirus Strain for Human Vaccination, Infec. & Immun., <u>12</u> (3): 521-527 (1975).
R4	Desai, et al., Mutations in Herpes Simplex Virus Type 1 Genes Encoding VP5 and VP23 Abrogate Capsid Formation and Cleavage of Replicated DNA, J. Virol., <u>67</u> (3): 1357-1364 (1993).
R5	Thomsen, et al., Assembly of Herpes Simplex Virus (HSV) Intermediate Capsids in Insect Cells Infected with Recombinant Baculoviruses Expressing HSV Capsid Proteins, J. Virol., <u>68</u> (4): 2442-2457 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.